Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2019 Symposium /
SPRING 01: Exploring the combination of avelumab, axitinib and palbociclib in patients with advanced metastatic NSCLC

23rd - 24th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.07.19
Views: 547

Dr Benjamin M. Solomon - Avera Cancer Institute, Sioux Falls, USA

Dr Benjamin Soloman speaks to ecancer at the WIN 2019 Symposium in Paris about the ongoing phase I/II SPRING 01 study, which focuses on patients with advanced, metastatic non-small cell lung cancer (NSCLC).

He explains the design of the trial, which includes the use of transcriptomics and genomics to predict therapeutic response to avelumab, axitinib and palbociclib in both normal and tumour tissue.

Dr Soloman also describes the second phase of the study, which involves enrolling patients in the first-line setting and mentions that this study could be expanded to other disease types in the future.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation